TABLE 4.
Infusion-related reactions in neutropenic patients receiving AmBisome
| Reaction | No. (%) of infusion-related reactions  in the following dosage cohorta: | ||||
|---|---|---|---|---|---|
| 1.0 mg/kg (n = 86) | 2.5 mg/kg (n = 61) | 5.0 mg/kg (n = 97) | 7.5 mg/kg (n = 87) | Total (n = 331) | |
| Temp elevation of ≥1°C | 1 (1.2) | 0 | 9 (9) | 5 (6) | 15 (5) | 
| Chills | 4 (5) | 0 | 3 (3) | 0 | 7 (2) | 
| Rigors | 0 | 1 (1.6) | 4 (4) | 1 (1.1) | 6 (2) | 
| Nausea | 0 | 0 | 0 | 0 | 0 | 
| Vomiting | 0 | 0 | 0 | 0 | 0 | 
| Headache | 0 | 0 | 0 | 0 | 0 | 
| Hypotensionb | 0 | 1 (1.6) | 0 | 0 | 1 (0.3) | 
| Hypertensionc | 0 | 0 | 1 (1) | 2 (2) | 3 (0.9) | 
| Dyspnea on infusion | 0 | 0 | 1 (1) | 1 (1.1) | 2 (0.6) | 
| Transient localized urticaria | 0 | 0 | 2 (2) | 0 | 2 (0.6) | 
| Generalized flushing reaction | 0 | 0 | 2 (2) | 0 | 2 (0.6) | 
| Premedicationd required for reaction | 0 | 0 | 4 (4) | 0 | 4 (1.2) | 
Infusion-related reactions are defined as reactions developing during infusion of the study drug. n, number of infusions.
Defined as a >25% decrease in systolic blood pressure.
Defined as a >25% increase in systolic blood pressure.
Benadryl, 50 mg given intravenously. (No other premedications were administered prior to the study drug.)